Lexeo Therapeutics Files 8-K

Ticker: LXEO · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1907108

Lexeo Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLexeo Therapeutics, Inc. (LXEO)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: filing, sec

Related Tickers: LXEO

TL;DR

LXEO filed an 8-K on Jan 13, 2025, confirming its Nasdaq listing. No major news.

AI Summary

Lexeo Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting its status as a registrant. The filing confirms its common stock trades under the symbol LXEO on the Nasdaq Global Market. No specific financial transactions or material events were detailed in this particular filing.

Why It Matters

This filing serves as a routine update for investors, confirming Lexeo Therapeutics' listing and trading status on the Nasdaq.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material information or financial events disclosed.

Key Players & Entities

  • Lexeo Therapeutics, Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of earliest event reported
  • LXEO (company) — Trading Symbol
  • Nasdaq Global Market (company) — Exchange

FAQ

What is the primary purpose of this 8-K filing for Lexeo Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report current information as required by the SEC, confirming Lexeo Therapeutics, Inc.'s status as a registrant and its trading details on the Nasdaq Global Market.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on January 13, 2025.

What is the trading symbol for Lexeo Therapeutics, Inc.'s common stock?

The trading symbol for Lexeo Therapeutics, Inc.'s common stock is LXEO.

On which exchange is Lexeo Therapeutics, Inc.'s common stock registered?

Lexeo Therapeutics, Inc.'s common stock is registered on the Nasdaq Global Market.

Does this 8-K filing disclose any new financial transactions or material events?

Based on the provided text, this 8-K filing does not appear to disclose any new specific financial transactions or material events; it primarily serves as a confirmation of the company's reporting status and trading information.

Filing Stats: 710 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2025-01-13 07:35:16

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LXEO Nasdaq Glo

Filing Documents

01 Other Events

Item 8.01 Other Events. On January 13, 2025, Lexeo Therapeutics, Inc. (the " Company ") posted on its website an updated corporate presentation (the " Corporate Presentation "). The Corporate Presentation will be used from time to time in meetings with investors and analysts. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Cautionary Note Regarding Forward-Looking Statements This report contains certain forward-looking statements regarding the business of the Company that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expected plans with respect to clinical trials of the Company's gene therapy candidates and the timing for announcement of data from such trials. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, expectations regarding the initiation, progress, and expected results of the Company's preclinical studies, clinical trials and research and development programs, the unpredictable relationship between preclinical study results and clinical study results, delays in submission of regulatory filings or failure to receive regulatory approval and liquidity and capital resources. Additional risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and subsequent future filings the Company may make with the Securities and Exchange Commission from time to time that are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements which are curre

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Corporate Presentation, dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lexeo Therapeutics, Inc. Date: January 13, 2025 By: /s/ R. Nolan Townsend R. Nolan Townsend, Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.